FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ashwin Gollerkeri

Research Profile

Chemicals & Drugs

Physiology

Drug Resistance, Neoplasm

Disorders

Concepts & Ideas

Procedures

Occupations

Co-author Network

Publications

TOP 3
Oliver G Ottmann; Hervé Dombret; giovanni martinelli; Bengt Simonsson; françois guilhot; Richard A Larson; Giovanna Rege-Cambrin; Jerald P Radich; Andreas Hochhaus; Anne Marie Apanovitch; Ashwin Gollerkeri; Steven Coutre
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
françois guilhot; Jane Apperley; Dong-Wook Kim; Eduardo O Bullorsky; Michele Baccarani; Gail J Roboz; Sergio Amadori; Carmino Antonio De Souza; Jeffrey H Lipton; Andreas Hochhaus; Dominik Heim; Richard A Larson; Susan Branford; Martin C Muller; Prasheen Agarwal; Ashwin Gollerkeri; Moshe Talpaz
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; françois guilhot; Giuseppe Saglio; Jane Apperley; Oliver G Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ashwin Gollerkeri (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Oliver G Ottmann; Hervé Dombret; giovanni martinelli; Bengt Simonsson; françois guilhot; Richard A Larson; Giovanna Rege-Cambrin; Jerald P Radich; Andreas Hochhaus; Anne Marie Apanovitch; Ashwin Gollerkeri; Steven Coutre
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Blood 2007;110(7):2309-15.
2007: françois guilhot; Jane Apperley; Dong-Wook Kim; Eduardo O Bullorsky; Michele Baccarani; Gail J Roboz; Sergio Amadori; Carmino Antonio De Souza; Jeffrey H Lipton; Andreas Hochhaus; Dominik Heim; Richard A Larson; Susan Branford; Martin C Muller; Prasheen Agarwal; Ashwin Gollerkeri; Moshe Talpaz
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Blood 2007;109(10):4143-50.
2007: Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; françois guilhot; Giuseppe Saglio; Jane Apperley; Oliver G Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood 2007;109(8):3207-13.
2005: Christopher R Garrett; Mayer N Fishman; Randall R Rago; Charles C Williams; Anne M Dellaportas; J Joseph Mahany; Richard M Lush; William S Dalton; Ashwin Gollerkeri; Marvin B Cohen; Daniel M Sullivan
Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3335-41.
2003: Ranjana Advani; George A Fisher; Bert L Lum; Charro Jambalos; Cheryl D Cho; Marvin Cohen; Ashwin Gollerkeri; Branimir I Sikic
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5187-94.